☆ 4.8 Article

Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19

JOURNAL OF CLINICAL INVESTIGATION (2021)

Related references

Note: Only part of the references are listed.

Review Virology

Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis

Soumya Sarkar et al.

Summary: Convalescent plasma therapy (CPT) may help reduce mortality, accelerate viral clearance, and improve clinical conditions in COVID-19 patients, but the existing evidence is of low quality. Further randomized controlled trials are needed to confirm the safety and effectiveness of CPT.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Immunology

Convalescent Plasma for Patients With Severe Coronavirus Disease 2019 (COVID-19): A Matched Cohort Study

Ralph Rogers et al.

Summary: The study did not find a significant difference in mortality risk or hospital discharge rate between patients treated with convalescent plasma and the control group. However, there was a signal for improved outcomes among elderly patients, and a higher frequency of transfusion reactions was observed in the convalescent plasma group. Further randomized studies focusing on the elderly subgroup are recommended.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Hematology

Convalescent plasma therapy in patients with COVID-19

Fevzi Altuntas et al.

Summary: This study indicated that convalescent plasma (CP) therapy can reduce the duration in the intensive care unit, rates of mechanical ventilation support and vasopressor support in severe and critically ill patients with COVID-19, as well as decrease the case fatality rate. Early administration of CP after COVID-19 diagnosis is associated with a better outcome in terms of mechanical ventilation support.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Review Hematology

How should we use convalescent plasma therapies for the management of COVID-19?

Erica M. Wood et al.

Summary: Convalescent plasma from blood donors with antibodies to SARS-CoV-2 may benefit COVID-19 patients by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal characteristics, transfusion volume, and administration timing remain to be determined, requiring international collaborative efforts to establish clinical efficacy. Preliminary safety data for COVID-19 CP is encouraging, with ongoing large, high-quality randomized trials starting to report preliminary results.

BLOOD (2021)

Add to Collection

Article Hematology

Early mortality benefit with COVID-19 convalescent plasma: a matched control study

Aarthi G. Shenoy et al.

Summary: The study demonstrated that patients with COVID-19 who received CCP had a decreased risk of death at 7 and 14 days, but not 28 days after transfusion, compared to matched controls.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Immunology

Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome *

Abolghasem Allahyari et al.

Summary: The study evaluated the safety and efficacy of convalescent plasma therapy for severe COVID-19 cases with ARDS, showing that early administration of convalescent plasma can contribute to the treatment of severe COVID-19 patients with mild or moderate ARDS by reducing mortality rate, disease severity, ICU stay, and need for intubation while increasing oxygenation levels.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC

Hyun ah Yoon et al.

Summary: Convalescent plasma therapy may be beneficial for COVID-19 patients, especially those under 65 years old. Pretransfusion antibody titers are associated with treatment efficacy.

JCI INSIGHT (2021)

Add to Collection

Review Medicine, General & Internal

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis

Perrine Janiaud et al.

Summary: Convalescent plasma treatment showed no significant decrease in all-cause mortality or benefit for other clinical outcomes compared to placebo or standard of care. The certainty of the evidence ranged from low to moderate for all-cause mortality and remained low for other outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Hematology

Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay

Erin Goodhue Meyer et al.

Summary: The efficacy of COVID-19 convalescent plasma (CCP) is believed to be linked to the concentration of neutralizing antibodies (nAb) to SARS-CoV-2. A study found that using surrogate binding antibody (bAb) signal-to-cutoff ratios (S/Co) to predict nAb titers can be effective, but the accuracy of the prediction decreases as target nAb titers increase.

TRANSFUSION (2021)

Add to Collection

Article Infectious Diseases

Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients - propensity-score matched case-control study

Adam Tworek et al.

Summary: This study confirmed a significantly lower mortality rate in patients treated with convalescent plasma, with no significant differences in ventilator time, ICU stay, and overall hospitalization time between the two groups. Age, cardiac insufficiency, active cancer, ventilator requirement, and length of hospitalization significantly increased the risk of death in both groups.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Peter W. Horby et al.

Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.

LANCET (2021)

Add to Collection

Article Medicine, Research & Experimental

Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults

Wesley H. Self et al.

Summary: The PassITON trial in the USA aims to provide high-quality evidence on the efficacy of COVID-19 convalescent plasma for treating adults hospitalized with acute moderate to severe COVID-19. With a planned enrollment of 1000 patients, the trial is designed to provide the most robust data available on the treatment of COVID-19 patients.

TRIALS (2021)

Add to Collection

Article Multidisciplinary Sciences

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

Manaf AlQahtani et al.

Summary: The pilot study suggests that CP therapy is safe in hospitalized COVID-19 patients, but there were no significant differences in primary and secondary outcome measures compared to standard therapy. A larger definitive study is needed for confirmation.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Multidisciplinary Sciences

Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors

Katie L. Kunze et al.

Summary: Successful COVID-19 therapeutics and vaccines have utilized the immune response to the virus, but locally-evolving variants may impact treatment effectiveness. Near-sourced convalescent plasma has higher efficacy in causing death within 30 days of transfusion.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Michael A. Thompson et al.

Summary: This study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19. Results showed that convalescent plasma treatment was associated with improved 30-day mortality, especially in patients requiring intensive care unit admission or mechanical ventilatory support.

JAMA ONCOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

Max R. O'Donnell et al.

Summary: This study found that the use of convalescent plasma was not associated with significant improvement in the clinical status at day 28 for severe COVID-19 patients, but it was related to significantly improved survival rates.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Geriatrics & Gerontology

Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis

Carolyn T. Bramante et al.

Summary: The study found that metformin significantly reduced mortality in female patients admitted for COVID-19 treatment with obesity or type 2 diabetes, but did not show a significant impact on mortality in male patients.

LANCET HEALTHY LONGEVITY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Interpreting Diagnostic Tests for SARS-CoV-2

Nandini Sethuraman et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Pathology

Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality

Eric Salazar et al.

AMERICAN JOURNAL OF PATHOLOGY (2020)

Add to Collection

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Article Hematology

Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study

Hassan Abolghasemi et al.

TRANSFUSION AND APHERESIS SCIENCE (2020)

Add to Collection

Letter Medicine, General & Internal

Change in Donor Characteristics and Antibodies to SARS-CoV-2 in Donated Blood in the US, June-August 2020

Roger Y. Dodd et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Sean T. H. Liu et al.

NATURE MEDICINE (2020)

Add to Collection

Letter Medicine, Research & Experimental

Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial

Fazle Rabbi Chowdhury et al.

TRIALS (2020)

Add to Collection

Letter Oncology

Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: Evidence from matched study and a meta-analysis

Weijun Jiang et al.

CLINICAL AND TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Political Science

Causal Inference without Balance Checking: Coarsened Exact Matching

Stefano M. Iacus et al.

POLITICAL ANALYSIS (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.